Profile
20/20 OptimEyes Technologies is developing OPT-101, a once-weekly, non-invasive glaucoma eye drop designed to address one of the largest challenges in glaucoma management: long-term patient adherence to daily therapy. Leveraging our proprietary Mucoadhesive NanoParticle (MNP) platform, OPT-101 is designed to improve treatment outcomes while maintaining the simplicity and accessibility of conventional topical therapies. With strong preclinical efficacy data, a low-risk 505(b)(2) regulatory pathway, and applicability within a large and rapidly growing global glaucoma market, OPT-101 is positioned to address a major clinical and commercial gap in chronic glaucoma care. The low cost-of-goods, scalable manufacturing, and broader applicability of the MNP platform also create opportunities for expansion across additional ophthalmic and mucosal delivery applications, supporting a scalable product development and licensing strategy with multiple future value inflection opportunities.
Website
2020optimeyes.caContact
-
Frances Lasowski, Chief Executive OfficerTel: +1 905 9789262Email: frances@2020optimeyes.ca
-
-
-
-
-
Event details
Event contact
Participants
-
20/20 OptimEyes Technologies is developing OPT-101, a once-weekly, non-invasive glaucoma eye drop designed to…
-
Altis Labs is the computational imaging company accelerating clinical trials with AI endpoints.… -
BioScript Solutions is a Canadian healthcare company committed to simplifying access to specialty care. BioScript… -
The Ottawa Hospital's Biotherapeutics Manufacturing Centre(BMC) is a cell and gene therapy… -
Custom Biologics provides regulatory compliant potency testing and assay services for all phases of… -
Dalriada is a Canadian small molecule discovery company focusing on unlocking challenging and undruggable targets… -
Located in Mississauga, Ontario, Eurofins CDMO Alphora delivers comprehensive solutions for small… -
Founded in 2004, Everest Clinical Research is a full-service contract research organization with more than 750… -
HDAX Therapeutics develops next-gen HDAC6 inhibitors for… -
i-RNA Corporation is a preclinical biotech developing siRNA… -
ImmunoBiochem is a pharma-partnered biotech developing novel degrader-antibody conjugate (DAC)… -
Medicenna is a clinical stage immunotherapy company developing novel and highly differentiated engineered long-… -
Noa Therapeutics is pioneering a breakthrough to the Aryl Hydrocarbon Receptor (AhR), a commercially… -
Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both… -
Paradox Immunotherapeutics is a venture-backed, clinical-inflection biotech tackling protein misfolding diseases… -
PharmAla Biotech (CSE:… -
PlantForm develops and manufactures proteins, antibodies, and vaccines at low cost using its green, plant-based… -
For over 32 years, Q&C Services has been Canada’s largest privately owned pharmaceutical consulting firm. Its… -
QurCan Therapeutics is advancing the next wave of genetic medicines for CNS… -
Spiderwort Biotechnologies is a clinical-stage regenerative medicine company pioneering a differentiated class of… -
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in Empowering Therapeutic… -
SYNG has developed, EndoID a new first-in-class diagnostic test for Endometriosis. It is… -
YYZPharmatech Inc. (“YYZ”) reveals and validates novel, proximal, functional co-receptor drug…